Combined BTK and PI3Kδ inhibition with acalabrutinib and ACP-319 improves survival and tumor control in CLL mouse model

PURPOSE: Targeting the B-cell receptor (BCR) pathway with inhibitors of BTK and PI3K-delta is highly effective for the treatment of chronic lymphocytic leukemia (CLL). However, deep remissions are uncommon and drug resistance with single-agent therapy can occur. In vitro studies support the effectiv...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:Clin Cancer Res
Päätekijät: Niemann, Carsten U., Mora-Jensen, Helena I., Dadashian, Eman L., Krantz, Fanny, Covey, Todd, Chen, Shih-Shih, Chiorazzi, Nicholas, Izumi, Raquel, Ulrich, Roger, Lannutti, Brian J., Wiestner, Adrian, Herman, Sarah E. M.
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: 2017
Aiheet:
Article
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC5626587/
https://ncbi.nlm.nih.gov/pubmed/28645939
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-17-0650
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia